Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 20, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering.

2025 Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...

Bayer (BAYGn.DE), opens new tab will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in ...

(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the company still faces after its $63 billion acquisition of ...